-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Biogen, Raises Price Target to $241

Benzinga·08/04/2026 18:11:00
語音播報
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.